Market Pulse

Fragile boards make willing sellers

The ValIndex Swiss Deal Count, our weekly tally of M&A-relevant commercial-register filings, reached 303 in the week of 29 June to 3 July 2026, the highest weekly count we have recorded and roughly double the prior week's level. Swiss merger law requires a fresh interim balance sheet once the accounts behind a merger are more than six months old, which makes 30 June the effective signing deadline for deals built on 31 December books.

ValIndex research: of the 38,913 audited companies in the Swiss Commercial Register, 12,362 (32%) would have no valid signature pair the day their principal signatory dies. Two of the four watch-component makers acquired by VAM Investments this week sat in those risk tiers.

Ipsen agreed on 1 July 2026 to acquire Zurich biotech Memo Therapeutics for EUR 200 million upfront and up to EUR 700 million with milestones, one of the larger Swiss biotech exits of 2026. The City of Zurich split SAP framework awards of roughly CHF 40 million across five vendors in the week's largest procurement prints.

7Press-Reported Deals+17% WoW
603Distress Events+23% WoW
2Startup FundingCHF 8.7M
20Succession Signals+186% WoW
1139New Registrations+18% WoW
2853Board Changes+40% WoW

The Swiss watch industry restructured from both ends this week. At the top, Damiani took Baume & Mercier, a maison founded in 1830, out of the Richemont stable. At the bottom, Milan's VAM Investments created Groupe Chaumont by acquiring four component makers at once: Efteor, Le Composant, Telos Watch and Henri Robert, more than one hundred employees across the Jura arc. The buyers are Italian, the debt is Swiss, and more add-ons are the stated plan.

Why do these firms sell? Our board-paralysis study measured one structural answer: of 38,913 audited Swiss companies, 32 percent would have no valid signature the day their principal director dies. Check this week's targets against that data. Telos Watch ran as a two-man board where neither partner can sign alone. Henri Robert paired one individual signer with a deputy who cannot act without him. Two of the four companies VAM just bought sat in the exact failure modes the study counts, visible in the register years before a buyer arrived.

From the research deskOne in three audited Swiss SMEs has no valid signature if its principal director dies32%Read the study

The same arithmetic closed smaller deals. FRISAG, a Zug specialty-chemicals maker founded in 1963, went to Max Lehner AG: its seller is a second-generation owner who is also the company's only registered director. The week's marquee exit shows the opposite pole: Ipsen is paying up to 700 million euros for Zurich's Memo Therapeutics, a syndicate-built company engineered from day one to be sold.

Underneath the named deals, the register had its loudest week since our count began: 303 M&A-relevant filings, roughly double a normal week. The reason is mechanical. Swiss merger law requires a fresh interim balance sheet once the accounts behind a merger are more than six months old, so contracts built on 31 December books had to be signed by Tuesday. The filings show the stampede: agreement after agreement dated mid to late June, balance sheet per 31 December 2025. One last pattern before you go: Italy bought Swiss three times this week, the component makers, the maison, the private-banking software. Different buyers, same read. Fragile governance and retiring founders reprice Swiss assets, and the register shows both to anyone who looks.

The balance sheets nobody publishes

Absorption filings are involuntary disclosure, and this week the register printed three balance sheets you will not find in any press release. Bruker Switzerland absorbed Chemspeed Technologies, the Fuellinsdorf lab-automation firm it bought in 2021, and the filing states the absorbed company was undercapitalised and overindebted: CHF 61.6 million of assets against CHF 99.6 million of third-party liabilities, with the auditor confirming Bruker holds free equity covering the shortfall. Bell Schweiz absorbed EISBERG Holding with a CHF 8.5 million excess of liabilities, backed by subordination declarations. And the largest transfer of the week was nearly invisible: Baloise Leben moved CHF 25.47 billion of assets onto Helvetia's life entity, the register's matter-of-fact record of the Helvetia Baloise integration. Intragroup debt often explains such structures, and none of this implies operating distress. But it is real financial disclosure of otherwise silent companies, and it only exists in the register.

The Signals

Unlock the signals — free

Pre-deal signals scored before the press, federal procurement prints, the complete deal tape, the forward court calendar and buyable estates. Free, every Friday.

Free weekly newsletter. Unsubscribe anytime.

Based on 7,306 SOGC/SHAB publications processed this week. M&A data sourced from Swiss commercial registry filings (303 SOGC), press-reported transactions via web intelligence (7 EXA), and startup funding from Startupticker, Tech.eu, and company disclosures (2 rounds). Company distress scoring based on proprietary multi-signal model across 113,000 Swiss companies. Valuation benchmarks supplemented from Deloitte Swiss M&A reports and Dealsuite DACH data.

ValIndex scores every Swiss merger, capital move, board change and distress signal as it hits the register, links each to the company, its owners and its succession risk, and maps entire industries end to end. This edition's study, deals and signals are all live on the platform. Request access →